The infectious profiles of biotherapeutic agents in an Algerian population (WCO-IOF-ESCEO 2016) - Apr 6, 2016 - Abstract #P589; P=NA, N=107; “The products used were adalimumab (33.6 %) etanercept (29 %) rituximab (13 %) tocilizumab (13 %) and infliximab (11.2 %)…Infections events are more common in anti-TNFα treated patients than those on rituximab or tocilizumab.”
Clinical data • Biosimilar • Immunology
|
|
WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases 14 –17 April 2016 Malaga, Spain
|
|
Background:The management of inflammatory arthritis has been revolutionized by the use of biologic therapy. However, infections represent the first cause of morbidity in people treated for chronic inflammatory diseases (CID) with biotherapy. The main objective of the study is to describe the incidence and risk-factors for infections in people treated with biotherapeutic agents (BA) for CID.
Methods: For a period of nine years, from January 2006 to December 2015, a prospective and descriptive study recruited all patients treated by biologics for CID. We reported all infections encountered during the treatment.
Results:We have identified 107 patients; indications for BA were mainly rheumatoid arthritis in 45 cases, ankylosing spondylitis in 34 cases, 20 for enteropathic arthritis and 8 for psoriatic arthritis. The products used were adalimumab (33.6 %) etanercept (29 %) rituximab (13 %) tocilizumab (13 %) and infliximab (11.2 %).There were 33 incidents of infections described. The majority of them were under corticosteroids and/or immunosuppressive drugs. Nine of them were diabetics, half of whom have a corticosteroidinduced diabetes. We have noted 23 viral infections, 10 bacterial infections, the most infections (N=19) were under anti-tumor necrosis factor alpha (anti-TNF, 3 under tocilizumab, 1 under rituximab. The overall infection rates were significantly increased after anti -TNFα treatment (P
Conclusions:Infections events are more common in antiTNFαtreated patients than those on rituximab or tocilizumab. The co-prescriptionofsteroidsandimmunosuppressive drugs is an additive risk factor. This underlines the importance of adherence to guidelines for their prevention and management.
|